durobinet schreef op 14 februari 2020 19:13:
[...]
About GLPG1690
GLPG1690 is a small molecule, selective autotaxin inhibitor which is fully proprietary to Galapagos.
Galapagos identified the autotaxin target using its proprietary target discovery platform and
developed molecule GLPG1690 as an inhibitor of this target. Oral investigational drug GLPG1690
showed promising results in relevant pre-clinical models for IPF, and there is growing evidence in
scientific literature that autotaxin plays a role in this disease. GLPG1690 appeared to halt disease
progression as measured by FVC at 12 weeks and was well-tolerated by IPF patients in the FLORA
Phase 2a trial reported in August 2017. Galapagos received orphan drug designation for GLPG1690